Open Orphan, Blencowe Resources and Alan Green on 3 Stocks
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Open Orphan, Blencowe Resources and Alan Green on 3 Stocks
Cathal Friel, Executive Chairman, Open Orphan #ORPH discusses a new contract they've signed, valued at £4m, with a top 3 global pharmaceutical company.
Open Orphan is a rapidly growing niche CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. Conducted from Europe's only 24-bedroom quarantine clinic with onsite virology providing individually isolated rooms and connected to our specialist laboratory facility which offers highly specialised virology and immunology laboratory services to support pre-clinical and clinical respiratory drug, antiviral, and vaccine discovery and development.
Mike Ralston, CEO of Blencowe Resources #BRES provides an update on all progress to date since its acquisition of the Orom-Cross Graphite Project in April.
Orom-Cross is a potential world class graphite project both by size and end-product quality, with a high component of larger flakes identified from previous work performed. A 21-year Mining Licence was issued by the Ugandan Government in 2019 following extensive historical work on the deposit. Orom-Cross presents as a large, shallow open pitable deposit, with an estimated resource in excess of 3 billion tonnes of graphite. Development of the resource is expected to benefit from a low strip ratio and free dig operations, thereby ensuring lower operating and capital costs. (Interview starts at 9 minutes 8 seconds)
Alan Green CEO of Brand Communications talks about:
Eddie Stobbart Logistics #ESL
Xpediator #XPD
BP #BP.
Union Jack Oil #UJO
(Interview starts at 16 minutes)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.